Insmed Incorporated vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends

Pharma SG&A Trends: Insmed vs. Amphastar

__timestampAmphastar Pharmaceuticals, Inc.Insmed Incorporated
Wednesday, January 1, 20144037300031073000
Thursday, January 1, 20154697400043216000
Friday, January 1, 20164729800050679000
Sunday, January 1, 20175091800079171000
Monday, January 1, 201858044000168218000
Tuesday, January 1, 201963109000210796000
Wednesday, January 1, 202065157000203613000
Friday, January 1, 202168920000234273000
Saturday, January 1, 202266592000265784000
Sunday, January 1, 202380393000344501000
Loading chart...

Unleashing insights

SG&A Expense Trends: Insmed vs. Amphastar

In the competitive landscape of pharmaceuticals, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Insmed Incorporated and Amphastar Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Insmed's SG&A expenses surged by over 1,000%, reflecting its aggressive expansion and investment in growth. In contrast, Amphastar's expenses grew by approximately 99%, indicating a more conservative approach.

Key Insights

  • Insmed's Growth: By 2023, Insmed's SG&A expenses reached nearly 3.5 times that of Amphastar, highlighting its strategic focus on scaling operations.
  • Amphastar's Stability: Despite a steady increase, Amphastar maintained a more stable expense trajectory, with a peak in 2023.

These trends underscore the differing strategies of these companies, offering investors a glimpse into their operational priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025